Developing Curative
Immunotherapies for PatientsTransformed by Drug Intelligence Science

Drug Intelligence Science (DIS^®) Enhances Clinical Success from Target to Patient

HiFiBiO Therapeutics is pioneering curative immunotherapies for patients with high unmet medical needs. The company is targeting the root cause of disease through its unique Drug Intelligence Science (DIS®) platform. DIS® enables the deep understanding of cellular pathology across various diseases through proprietary single cell technology and AI/ML analytics. This platform is being deployed in target discovery, antibody selection, and predictive biomarker identification to achieve enhanced clinical success for patients.

Proven Track Record of Therapeutic Innovation

We started in 2017 with the goal of leveraging deep immune modulation expertise and cutting edge single cell technology to deliver transformative medicines to patients.

News

Apr 29, 2025HiFiBiO Therapeutics to Present Preclinical Data for A Novel Immunology Antibody at the 2025 Annual Meeting of the Clinical Immunology Society 

Nov 04, 2024HiFiBiO Therapeutics Receives FDA Clearance of IND Application for HFB200604, a Best-in-Class BTLA Agonist Antibody for the Treatment of Inflammatory and Immunology Diseases 

Oct 07, 2024HiFiBiO Therapeutics to Showcase DIS® Enabled Translational Insights from Ongoing Phase 1 Clinical Trials for Two Novel Immuno-Oncology Antibodies at the 2024 Annual Meeting of the Society for Immunotherapy of Cancer (SITC)